

## CTSC May newsletter

Clinical & Translational Science Center <HSC-CTSC@salud.unm.edu>

Thu 4/29/2021 3:28 PM



## Clinical & Translational Science Center Newsletter

May 2021

### Letter from the Director



Dear Colleagues,

We hope you and yours are well as we start another active month of research at the CTSC.

In our featured stories this month, we highlight the Wide Engagement for Assessing COVID-19 Vaccination Equity (WEAVE NM) project, which will take a wide collaborative approach to address vaccine hesitancy in New Mexico. WEAVE NM will examine the systemic and policy barriers that contribute to hesitancy from a racial equity lens. Additionally, several CTSC cores have exciting virtual events. Faculty researchers will find value in the Database of Individual Patients' Experiences (DIPEX) methodology training from May 12 to May 14. Collaboration-minded researcher and those interested in connecting with local biotechnology businesses will find value in the CTSC BioVenture Partnership Event on May 19. Finally, researchers and clinicians alike should consider attending the Southwest Clinical Trial Network's Community Advisory Group meeting on June 16, where Dr. Larry

Leeman will present about the buprenorphine microdosing protocol currently in the pilot stage.

We also have updated information on COVID-19 funding opportunities. We encourage you to look for the weekly memos for current information and funding opportunities.

COVID-19 vaccine self-scheduling is now available for New Mexicans 16 years and older. Schedule an appointment on the New Mexico Department Health website: <https://vaccinenm.org>. The CDC advises good COVID-safety habits, including social distancing and masking, for those who have received the vaccine.

All standard CTSC services are available at this time. We encourage PIs to reach out to our Research Concierge ([HSC-CTSCResearchConcierge@salud.unm.edu](mailto:HSC-CTSCResearchConcierge@salud.unm.edu)) with questions and/or to setup a consultation with the CTSC team.

We endeavor to update each section of the CTSC newsletter monthly. Every part of the CTSC is integral to our purpose and funding. Each PI has a personal, professional investment in the information we provide. Please submit that information to our team. The CTSC is here for your support.

The committed faculty, staff, and students at CTSC continue their research projects and look for innovative ways to support our communities. If you are interested in a rigorous quantitative rural research project focused on COVID-19, please contact me ([RLarson@salud.unm.edu](mailto:RLarson@salud.unm.edu)) to start a dialogue.

The Health Sciences Center Office of Research website contains information on specific research-related updates (including the Research Continuity Guidelines for both [Laboratories & Research Facilities](#) and [Clinical Trial Research Faculty & Staff](#)) and can be accessed through the following link: <https://hsc.unm.edu/research/>.

Should you have any questions about our assets and services, please contact the CTSC Research Concierge at [HSC-CTSCResearchConcierge@salud.unm.edu](mailto:HSC-CTSCResearchConcierge@salud.unm.edu). If you have any issues finding the information that you need, please reach out to [the CTSC Newsletter Team](#) and they will get back to you.

As always, thank you so much for your continued support of the Clinical & Translational Science Center!

Warm regards,

Richard S. Larson, MD, PhD

PI, CEO and Director, Clinical & Translational Science Center

## CTSC Leadership

**CTSC Director, CEO & Principal Investigator:** Richard S. Larson, MD, PhD

**Associate Director, CTSC:** Matthew Campen, PhD

**Associate Director, CTSC:** Nancy Pandhi, MD, PhD, MPH

**Chief Administrative Officer:** Carla Cordova, MPH

**Administrative Component Director:** Beth Tigges, PhD, RN, PNP, BC

**Tracking & Evaluation Module Lead:** Beth Tigges, PhD, RN, PNP, BC

**Quality & Efficiency Module Lead:** Beth Tigges, PhD, RN, PNP, BC

**Informatics Component Director:** Christophe Lambert, PhD

**Community & Collaboration Component Director:** Mark Unruh, MD

**Community Engagement Module Lead:** Nancy Pandhi, MD, PhD, MPH

**Collaboration and Commercialization Module Lead:** Eric Prossnitz, PhD

**Translational Endeavors (TE) Component Director:** Christopher Abbott, MD

**Translational Workforce Development (TWD) Module Lead:** Karlett Parra, PhD

**Pilot Translational & Clinical Studies (PTC) Module Lead:** Corey Ford, MD, PhD

**Research Methods (RM) Component Director:** Mark Unruh, MD

**Biostatistics, Epidemiology & Research Design (BERD) Module Lead:** Mark Unruh, MD

**Regulatory Knowledge & Support (RKS) Module Lead:** Corey Ford, MD, PhD

**Hub Research Capacity (HRC) Component Director:** Nancy Pandhi, MD, PhD, MPH

**Integration of Special Populations (ISP) Module Lead:** Nancy Pandhi, MD, PhD, MPH

**Participant Clinical Interactions (PCI) Director:** Christopher Abbott, MD

**Network Capacity (NC) Component Director:** Hengameh Raissy, PharmD

**Trial Innovation Network (TIN) Module Lead:** Hengameh Raissy, PharmD

**Drug Discovery & Repurposing Core Lead:** Hakim Djaballah, PhD

**Opioid-Use Populations with Integration, Outreach, Informatics, and Drug Discovery (OPIOIDD) Module Lead:** Kimberly Page, PhD, MPH

**KL2 Mentored Career Development Component Director:** Matt Campen, PhD

**Clinical Laboratory Medical Director:** Qian-Yun Zhang, MD, PhD

## Featured Stories

### ***WEAVE NM Project To Address Vaccine Hesitancy in New Mexico***

CTSC's community engagement core will be working closely with the recently funded Wide Engagement for Assessing COVID-19 Vaccination Equity (WEAVE NM) project, which will be taking a deep dive into understanding the social ecology of vaccine hesitancy across New Mexico. WEAVE NM is a collaborative project between Lisa Cacari Stone of the of the Transdisciplinary Research Engagement and Equity Center, Dr. Tassy Parker of the Center for Native American Health, and Dr. Nina Wallerstein of the Center for Participatory Research. By working with the NIH and partners in other states, WEAVE NM will be able to go beyond understanding individual behavior changes to increasing vaccine hesitancy, to looking at the systems and policy barriers from a racial equity lens. The project will engage with communities across our state and using innovative methodologies such as digital policy stories (across urban and rural racial/ethnic communities), catalyst films. By leveraging community partnership assets and trusted relationships, WEAVE NM will achieve maximum impact in understanding and addressing vaccine hesitancy.

### ***DIPeX Training May 12-14, 2021***

The Health Experiences Research Network is offering a virtual training from May 12th to May 14th, 2021 via Zoom. All attendees will be trained on the implementation of the Database of Individual Patients' Experiences (DIPeX) methodology, topic selection, recruitment, qualitative interviewing, and online module development.

The price of this training is \$180 for students and residents and \$380 for all others. If you are a faculty or staff member at the University of New Mexico there is an option for using tuition remission as well. [Please register here](#). More information will be sent over the coming months regarding a brief, mandatory asynchronous training course and meeting.

If you have any questions about the training, please contact Jeff Carter at [jeacarter@salud.unm.edu](mailto:jeacarter@salud.unm.edu) for more information. Thank you!

### ***2021 CTSC BioVenture Partnership Event on May 19, 2021***

CTSC in collaboration with ASCEND Accelerator HUB are pleased to announce the 2021 CTSC BioVenture Partnership Event on Wednesday, May 19, 2021 - 2:30 PM - 5:30 PM. This is a virtual event hosted on Zoom. The BioVenture Partnership event creates opportunities for both the academic and local biotech business to connect, explore partnerships to boost the state's biotech economy, and to help move research out of the lab and into the market.

Participation is open to all UNM faculty, students, and biotech companies.

This is an excellent opportunity to showcase your latest research findings, share your non-confidential work with your colleagues, and receive valuable feedback from peers and industry experts.

- General Registration is open through May 18, 2021.
- Register online: [goto.unm.edu/bioventure](https://goto.unm.edu/bioventure)

For additional information and to register for upcoming Synergy meetings, please visit the webpage: <https://hsc.unm.edu/research/ctsc/programs/team-science.html>.

Find out more about ASCEND Hub resources and activities on the ASCEND Hub website: <https://ascendhub.org>.

### **Southwest Clinical Trials Network Presentation on Buprenorphine Microdosing on June 16, 2021**



The CTSC OPIOIDD function is happy to announce the upcoming quarterly Southwest Clinical Trials Network's Community Advisory Group Meeting, on Thursday June 16, 2021 from 12:00pm-1:00pm. Special Focus of the CAG: Dr. Larry Leeman will present about the exciting new Buprenorphine Micro-dosing protocol currently being piloted in the UNM Milagro Clinic. A buprenorphine micro-dosing protocol carries the benefits of avoiding the need for pregnant patients to enter withdrawal, and occurring outpatient regardless of gestational age. A Q&A session will follow the presentation.

All are welcome to attend this important meeting. To register, please visit:

<https://hsc-unm.zoom.us/meeting/register/tJckf-moqT4rH9x-Kw0-dE6hga26f46jd7HH>

For more information, please contact Dr. Page at [pagek@salud.unm.edu](mailto:pagek@salud.unm.edu).

## Menu of Services & Resources

- [Biostatistics Support](#)
- [Brain & Behavioral Disorders](#)
- [Citing the Clinical & Translational Science Center](#)
- [Clinical Trials Participant Clinical Interactions](#)
- [Community Engagement](#)
- [Community Health Network](#)
- [Database Mining](#)
- [Drug Repurposing](#)
- [KL2 Scholars](#)
- [Intramural Funding](#)
- [Laboratory Services](#)
- [Pilot Funding](#)
- [Trial Innovation Network](#)
- [Quality & Efficiency](#)
- [Regulatory Knowledge & Support](#)
- [Rural Health Research](#)
- [Team Science & Commercialization](#)
- [Training](#)
- [Vulnerable Populations](#)

## Administration

### Tracking & Evaluation (T&E)

The Tracking and Evaluation Team is piloting a new "Common Metric" called the Median Accrual Metric. This metric is intended to look at our CTSC's ability to recruit and retain research participants. This metric will look at the entire calendar year for 2020 and will be reported in August of 2021.

### Quality & Efficiency (Q&E)

The Quality and Efficiency Team continues to work on two specific process improvements initiatives. These two projects will conclude in June of 2021 and will be evaluated for how the projects impacted our CTSC.

## Informatics

### **Dr. Laura Nervi Developing Health Literacy App with CTSC Team**

According to the Centers for Disease Control, over a third of adults in the U.S. have low health literacy. Low health literacy prevents people from making appropriate health decisions, and is especially prevalent in minority populations, the medically underserved, the elderly, and those with a low socioeconomic status. Dr. Laura Nervi is working with the CTSC Informatics App Team to develop a smartphone app which will address this gap in Spanish speakers. Her pilot project seeks to deliver a science-based health literacy and English as a Second Language (ESL) program for Spanish-speakers through an interactive language and health smartphone application. The content is based on the Health Literacy and English as a Second Language Curriculum previously developed by a team led by Dr. Francisco Coto Mas.

The program will include chronic disease prevention and disease management content. While it is a prototype, the objective is to obtain more funding to make the application more robust (and ready to be tested by the community partners and future users). The first phase is fully functional for pilot testing. The pilot project has developed an Android-compatible application, and the team has plans to develop an iOS version as well. The new language/health learning program will significantly increase autonomy, self-efficacy, and access to healthcare among Spanish speakers.

### **Data Requests & “Using Data Courses”**

The CTSC’s Informatics core has helped hundreds of clinical researchers leverage UNMH’s electronic health records and other medical databases to find eligible subjects for clinical trials, evaluate medical practice trends, and conduct longitudinal research projects upon nationwide cohorts. If you are interested in finding out more about how to use big data in your research, please read the descriptions of our “Using Data Courses” <https://hsc.unm.edu/ctsc/training/training-catalog.html>, you may also register on this same webpage to attend the course. If you are interested in an overview for your staff or faculty zoom meeting, please contact [mvalencia-reed@salud.unm.edu](mailto:mvalencia-reed@salud.unm.edu) to arrange for a presentation.

Informatics also supports REDCap, if you have any questions about REDCap, please contact the REDCap Support Team at [ctscredcap@salud.unm.edu](mailto:ctscredcap@salud.unm.edu).

## Community & Collaboration (C&C)

### Community Engagement & Research Core (CERC)

#### **CERC Supporting NIMH Addiction Treatment Study**



Dr. Kimberly Page, Professor in the Division of Epidemiology, Biostatistics, and Preventive Medicine in the Department of Internal Medicine is conducting a randomized controlled trial: Collaboration Leading to Addiction Treatment and Relief from Other Stressors (CLARO). This project is funded by the National Institute of Mental Health (NIMH). The University of New Mexico in collaboration with the RAND Corporation are partnering with 13 community healthcare clinics across New Mexico from three health

systems (First Choice Community Healthcare, Hidalgo Medical Services, and UNM Family and Community Medicine). The goal of this project is to test whether or not a collaborative care model can improve access, quality, and outcomes for patients with Opioid Use Disorder (OUD) and co-occurring PTSD and/or depression.

The project plans to recruit 1200 patients over the next 18 months. Half of these patients will receive usual care, while the

other half will receive the collaborative care intervention. Patients randomized to collaborative care will work with a care coordinator who will help them access and stay in care. The two groups will be compared based on multiple outcomes, including substance use, how many begin and stay in treatment; how depression and PTSD symptoms change; and how other outcomes such as physical and mental health and wellbeing are affected.

CERC is supporting this multisite trial by helping screen and enroll participants, as well as administering the baseline interviews and randomizing the participants. The research team screens participants for co-occurring mental health conditions and OUD, collects information on substance use, mental health, and various social determinants of health. The CERC staff have been successful at engaging patients in both the rural and urban communities virtually via zoom and telephone. The study has enrolled 130 participants to date!

## Translational Endeavors (TE)i

### Translational Workforce Development (TWD)

#### **Course Offerings and Consultations – Free of Cost**

Translational Workforce Development has numerous [course offerings](#) and can even provide consultations as requested to assist you in your goals! Please request a [consultation](#) or additional information on any courses offered. The TWD team may be reached via [HSC-CTSCTWDTraining@salud.unm.edu](mailto:HSC-CTSCTWDTraining@salud.unm.edu).

For information regarding TWD, please visit our webpage: <https://hsc.unm.edu/research/ctsc/training/index.html>.

### Pilot Awards

The UNM CTSC provides a variety of Pilot Award Programs that distribute intramural funding for clinical and translational research at the Health Sciences Center, including two rounds of funding for our standard RFAs annually. To access a Funding Calendar of CTSC opportunities, please use this link: <https://hsc.unm.edu/research/ctsc/pilot-funding/funding-calendars/index.html>.

Please visit our web site at <https://hsc.unm.edu/research/ctsc/pilot-funding/index.html> for additional information.

## Research Methods (RM)

### Biostatistics, Epidemiology, and Research Design (BERD)

#### **Biostatistics Consultation Services Available at CTSC**

The Biostatistics, Epidemiology, and Research Design (BERD) Core provides consultation and services, novel tools and methods intended to solve problems, and address barriers to the conduct of clinical and translational research. Services are open to all Health Sciences investigators (staff, students, and faculty) to understand the methodological aspects of their research for planning their projects, including power analysis, sample size, and research design for intermural and extramural grant submissions.

If you have a current pilot study that requires biostatistical support, please schedule appointments as soon as possible.

Are you interested in applying for a pilot study? It is strongly recommended that you make an appointment with one of our biostatisticians prior to your submission. Our expert biostatisticians can help in the initial stages of project development.

Appointments are available; but do fill up quickly. To schedule an appointment, please contact

[HSC-CTSCbiostats@salud.unm.edu](mailto:HSC-CTSCbiostats@salud.unm.edu). Services are offered Monday through Friday.

Please visit our web site: <http://hsc.unm.edu/research/ctsc/biostatistics/index.html>.

## Regulatory Knowledge & Support (RKS)

### IRB Post Approval Monitoring (PAM) & Audits

The UNMHSC Human Research Protections Office is committed to ensuring that all approved research is conducted in accordance with the IRB approved protocol, federal and state regulations, UNM's institutional policies, and the ethical principles outlined in the Belmont Report. The primary goal of the compliance monitoring is to provide the most current information to investigators through education, training, and monitoring. Upon selection for a PAM, the Principal Investigator will be notified in writing two weeks in advance.

The reason(s) for on-site review may include:

- random selections as part of a regular PAM cycle
- when IRB have cause that a non-compliance has occurred,
- when there is unanticipated problems involving risk to subjects or others
- subject or whistleblower complaints
- requests by an investigator to review their human subject processes

The CTSC Regulatory Knowledge Support (RKS) can assist investigators in preparing for their Post Approval Monitoring visit.

Please contact the CTSC Research Concierge @ [HSC-CTSCResearchConcierge@salud.unm.edu](mailto:HSC-CTSCResearchConcierge@salud.unm.edu) for knowledge, assistance and updates regarding any regulatory requirements.

<http://hsc.unm.edu/research/ctsc/regulatory-knowledge-and-support/index.html>

## Hub Research Capacity (HRC)

### Integrating Special Populations (ISP)

The Health Experiences Research Network, launched in 2014, is a partnership between researchers at University of Wisconsin-Madison, Johns Hopkins University, Oregon Health & Science University, Yale University, University of New Mexico, University



of Utah-Salt Lake City, and the Veterans Administration. We're using our combined talents as researchers, innovators, and health care professionals, and our experiences as patients, parents, caregivers, and advocates to bring you real information on the experience of health and illness from a wide range of patients. HERN is committed to implementing the Database of Individual Patient Experiences (DIPEX) methodology in the United States so that each qualitative research study is conducted with rigor and its corresponding public-facing web-based "module" is interpretive, deeply descriptive, and holistic.

Once we have our established themes, they are presented as web-based modules at [www.healthexperiencesusa.org](http://www.healthexperiencesusa.org). What we learned is organized by categories and topics that help visitors to the website discover what is relevant to them. We take special care to retain the voices of those we interviewed and include relevant clinical and background information. (source: [www.healthexperiencesusa.org](http://www.healthexperiencesusa.org))

The UNM CTSC ISP team will be hosting a national web-based training for researchers and staff interested in learning about using this methodology on **May 12-14, 2021**. To learn more, please contact Heidi Rishel Brakey at [hrihelbrakey@salud.unm.edu](mailto:hrihelbrakey@salud.unm.edu).

## Participant Clinical Interactions (PCI)

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure (hypertension) in the arteries of the lungs (pulmonary artery) for no apparent reason. The pulmonary arteries are the blood vessels that carry blood from the right side of the heart through the lungs. Symptoms of PAH include shortness of breath (dyspnea) especially during exercise, chest pain, and fainting episodes. The exact cause of PAH is unknown and although treatable, there is no known cure for the disease. PAH usually affects women between the ages of 30-60. Individuals with PAH may go years without a diagnosis, either because their symptoms are mild, nonspecific, or only present during demanding exercise. However, it is important to treat PAH because without treatment, high blood pressure in the lungs causes the right heart to work much harder, and over time, this heart muscle may weaken or fail.

Dr. Lana Melendres-Groves, is an Associate Professor in the Department of Internal Medicine's Division of Pulmonary, Critical Care and Sleep Medicine and serves as the PI for the trial: Upravi: Selexipag- The Users Drug Registry (SPHERE). This is a prospective observation drug registry developed to examine the clinical characteristics and outcomes, as well as dosing regimens of patients treated with Upravi. Selexipag was recently approved by the FDA for the treatment of PAH. The rationale behind this observational study is to further outline the clinical characteristics, outcomes and dosing/titration regimens of patients treated with Upravi in routine clinical practice.

The UNM CTSC Participant and Clinical Interactions team is supporting Dr. Lana Melendes-Groves in this trial. The PCI research nurse conducted chart reviews of those patients enrolled in this study in order to provide the data needed by the trial.

For more information on how the PCI unit can help in research, please email Donna Sedillo at [dlsedillo@salud.unm.edu](mailto:dlsedillo@salud.unm.edu).

## Community Health Network (CHN)









The Community Health Network (CHN) continues to make connections with our neighboring communities in rural New Mexico. Cynthia Killough, the program manager, has been attending as many virtual community health council meetings around the state as possible. These meetings provide a wealth of information about health disparities and concerns that are important to rural communities. The meetings also provide a way for Cynthia to introduce health research at UNM and help break down stigma associated with research in general.

One strategy Cynthia has been using to continue to engage communities in research is to connect them to other resources at UNM HSC. Cynthia recently collaborated with librarians Jonathan Pringle and Kelleen Maluski on creating a simple one-pager to help stop the spread of (health) misinformation. The one-pager contained 4 questions derived from a resource given to students on how to evaluate resources of information: <https://libguides.health.unm.edu/evaluating/home#s-lg-box-wrapper-30956843>.

The questions are: 1.) Who wrote it? 2.) Who was this written for? 3.) What's the purpose? and 4.) Where's the information coming from? Take these questions geared towards the general public, instead of the original academic view, Cynthia reached



out to several community members across the state to help evaluate and find just the right wording. The questions, which had been further translated into Spanish, were then reviewed and approved by the New Mexico Department of Health (NMDOH), as well as the HSLIC marketing team. The NMDOH loved the idea of the one-pager and found it so helpful that they had it translated into Navajo (pictured), Vietnamese and Arabic. Misinformation can be so detrimental to the health of our communities and it is important we all evaluate sources of information with a critical eye.

<p style="text-align: center;">Help stop the spread of misinformation <b>There's so much information out there!</b> Here are some questions to ask yourself to sort through it all.</p> <div style="text-align: center;">   <b>Who wrote it?</b> What are their credentials?         </div> <div style="text-align: center;">   <b>Who was this written for?</b> Patients? Doctors?         </div> <div style="text-align: center;">   <b>What's the purpose?</b> To relay news? Are all the facts being represented?         </div> <div style="text-align: center;">   <b>Where's the information coming from?</b> What are their stated priorities?         </div>	<p style="text-align: center;">Nihiká anilyeed yooch'íid bee hane' ní' ádoonííí <b>Yooch'íid hane' t'óó ahayóí t'áá aktsogóó!</b> Kót'éego na'ídkidgo bee ní' bééhozin doo.</p> <div style="text-align: center;">   <b>Hái lá hane' áyíilaa?</b> Binaaltsos hait'éhígíí bee hólo?         </div> <div style="text-align: center;">   <b>Hái lá hane' bich'í' ályaa?</b> Azee' bee bíká anída'alwo'ígíí? Azee'íí'íni?         </div> <div style="text-align: center;">   <b>Ha'át'íí biniyé hane' ályaa?</b> Ádahoónííí baa hane' altah yit'áái? T'áá aaníí ádaat'éii daats'í yaa halne'?         </div> <div style="text-align: center;">   <b>Háádéesh hane' yit'ih?</b> Ha'át'íí lá aláají' nayiinilgo halne'?         </div>
---	---

## Network Capacity (NC)

### Trial Innovation Network (TIN)

The Trial Innovation Network is a collaborative initiative within the CTSA Program and is composed of three key partners: the CTSA Program Hubs, the Trial Innovation Centers (TICs), and the Recruitment Innovation Center (RIC).

The vision for the Trial Innovation Network is to innovatively address critical roadblocks in clinical research and accelerate the translation of novel interventions into life-saving therapies.

The Trial Innovation Network is a collaborative national network with a focus in three main areas: operational innovation, operational excellence and collaboration. The Trial Innovation Network will leverage the expertise and resources of the CTSA Program. The Trial Innovation Network will feature a single IRB system, master contracting agreements, quality by design approaches, and a focus on evidence-based strategies to recruitment and patient engagement.

The goal of the Trial Innovation Network is to not only execute trials better, faster, and more cost-efficiently but, importantly, to be a national laboratory to study, understand and innovate the process of conducting clinical trials.

The University of New Mexico CTSC has been a part of the Trial Innovation Network and as a result has been a participating site in several studies that impact a variety of disease states. This important work has helped connect physicians at the University of New Mexico with the clinical trials specific to their specialty. This effort has encouraged new investigators to become engaged in clinical research. This collaboration is part of the larger mission to move innovated research from the bench, to the bedside, and ultimately out into the communities in which we live.

For more information on the Trial Innovation Network, please contact George Garcia at [gemgarcia@salud.unm.edu](mailto:gemgarcia@salud.unm.edu).

## Drug Discovery & Repurposing Core (DDRC)

### ***The DDRC is a Resource for Rapidly Translating Existing Drugs into New Clinical Trials***

Do you have ideas about ways to repurpose existing FDA-approved drugs? The CTSC is here to help. Dr. Hakim Djaballah, Module Lead for the Clinical & Translational Science Center Drug Discovery and Repurposing Core (DDRC) collaborates with UNM investigators other CTSCs to improve health outcomes by providing unique resources for rapidly translating existing drugs for use in new clinical trials. DDRC provides access to and operation of state-of-the-art technology in drug rescue, repurposing,

and repositioning through innovative tools that support investigators and start-up companies. Additionally, DDRC provides support and guidance in translating pilot projects from preclinical proof-of-principle to clinical proof-of-concept as well as helps to develop first-in-human clinical trials.

For additional information or to become a DDRC member, please visit the DDRC (formerly DR3N) webpage- <https://hsc.unm.edu/research/ctsc/dr3n/index.html>

## Clinical Laboratory (T-Laboratory)

The CTSC Translational Laboratory (T-Laboratory) is comprised of 6,000 square feet of wet-lab space, located in the newly renovated CTSC Building. The T-Laboratory offers state-of-the-art equipment and technical assistance with laboratory techniques for UNM HS investigators. The experienced staff of the T-Laboratory provide specialized laboratory support, customized to meet the needs of the investigators in all aspects of research including protocol/assay development, budget preparation, and testing of patient samples for various assays. The T-Laboratory provides sample preparation and technical support for other non-CTSC resources such as UNM Shared Flow Cytometry and High Throughput Screening Resource, and KUSAIR Small Animal Imaging. In addition, our staff will provide training to UNM HS investigators staff on molecular techniques, clinical techniques, or equipment. There are three options for utilization of CTSC T-Laboratory Services:

- Option A: Full Service Sample Testing
- Option B: Equipment Utilization by Investigator
- Option C: Preparation of Investigator's Experiments or Train Investigator's Staff to Perform Assays and Equipment.

Additionally, the CTSC Clinical Laboratory develops and carries out research-related sample analyses for UNM HS investigators, researchers throughout the United States and world, as well as corporate funded research projects.

For questions, please contact [HSC-CTSCResearchConcierge@salud.unm.edu](mailto:HSC-CTSCResearchConcierge@salud.unm.edu).

### Funding Opportunities Specific to COVID-19

There are several significant funding opportunities available through the CTSC to address the COVID-19 pandemic. CTSC monitors these opportunities for our HSC faculty on a weekly basis and includes additional information from the NIH COVID-19 funding site for your convenience.

Some of these funding opportunities require an active grant or cooperative agreement. They may also need a Letter of Support from Dr. Larson, the CTSC PI. Please contact Michelle Parra ([MMParra@salud.unm.edu](mailto:MMParra@salud.unm.edu)) if you are interested in applying for any of the COVID-19 funding opportunities listed below.

Recent Active Funding Opportunities Specific to COVID-19 are listed below:

Title	Notice Number	Organization(s)	Release Date	RFA/PA/ PAR #	Expiration Date	Activity Code(s)
Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for the Clinical and Translational Science Award (CTSA) Program to Address COVID-19 Public Health Needs	<a href="#">NOT-TR-21-022</a>	<a href="#">NCATS</a>	Feb 26, 2021	<a href="#">PA-20-135</a>	Aug 17, 2021	333
Notice of Special Interest (NOSI): Neurological and Neurocognitive	<a href="#">NOT-AG-21-016</a>	<a href="#">NIA</a>	Feb 26, 2021	<a href="#">PA-20-185</a> <a href="#">PA-20-183</a> <a href="#">PA-20-184</a> <a href="#">PA-20-195</a>	May 8, 2023	R01, R21, R03

Sequelae from SARS-CoV-2 Infection and COVID-19 in Aging and Age-Related Neurodegeneration				<a href="#">PA-20-194</a> <a href="#">PA-20-196</a> <a href="#">PA-20-200</a>		
Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions for Modeling Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2	<a href="#">NOT-GM-21-019</a>	<a href="#">NIGMS</a>	Feb 25, 2021	<a href="#">PA-18-935</a>	Dec 16, 2021	333
Notice of Special Interest (NOSI): Telehealth Strategies for Individuals with HIV and Substance Use Disorders	<a href="#">NOT-DA-21-019</a>	<a href="#">NIDA</a>	Feb 10, 2021	<a href="#">PA-20-184</a> <a href="#">PA-20-183</a> <a href="#">PA-20-200</a> <a href="#">PA-20-195</a> <a href="#">PA-20-194</a> <a href="#">PA-20-196</a> <a href="#">PA-20-146</a>	Sep 8, 2024	R01, R03, R21
Notice of Special Interest (NOSI) Announcing the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus	<a href="#">NOT-DA-21-041</a>	<a href="#">NIDA</a>	Apr 15, 2021	<a href="#">PA-20-272</a> <a href="#">PA-18-935</a> (Urgent Supplement)	Mar 31, 2022	333
Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations RADx-UP Phase II (U01 Clinical Trial Optional)	<a href="#">RFA-OD-21-008</a>	<a href="#">NIH, NIBIB, NIDDK, NIEHS, NIMH, NINDS, NINR, NIA, NIAAA, NIDCD, NIDA, NIMHD, NLM, OBSSR, ODP, SGMRO, THRO, NIDCR, NHLBI, ECHO, NICHD, NCI, NCATS, NCCIH, NEI, NHGRI, NIAID, NIAMS, NIGMS, ORWH</a>	Apr 13, 2021	<a href="#">RFA-OD-21-009</a> , <a href="#">U01</a> Research Project (Cooperative Agreements) <a href="#">NOT-OD-21-103</a> <a href="#">NOT-OD-21-101</a>	Jul 8, 2021	U01
Notice of Special Interest (NOSI): Medical Consequences of Smoking and Vaping Drugs of Abuse in Individuals with HIV and COVID-19	<a href="#">NOT-DA-21-017</a>	<a href="#">NIDA</a>	Feb 4, 2021	<a href="#">PA-20-184</a> <a href="#">PA-20-183</a> <a href="#">PA-20-200</a> <a href="#">PA-20-195</a> <a href="#">PA-20-194</a> <a href="#">PA-20-196</a>	Sep 8, 2024	R01, R02, R03
Notice of Special Interest (NOSI): Complement in Basic Immunology (CIBI)	<a href="#">NOT-AI-21-008</a>	<a href="#">NIAID</a>	Feb 4, 2021	<a href="#">PA-20-185</a> <a href="#">PA-20-195</a>	Jan 8, 2023	R01, R21
Notice of Special Interest (NOSI): Urgent Competitive Revisions and	<a href="#">NOT-MD-21-012</a>	<a href="#">NIMHD</a>	Feb 4, 2021	<a href="#">PA-20-272</a> <a href="#">PA-18-935</a> (Urgent Supplement)	May 4, 2021	333

<b>Administrative Supplements for Research at NIMHD Research Centers in Minority Institutions (RCMI U54s) on SARS-CoV-2 Vaccine Hesitancy, Uptake, and Implementation</b>						
<b>Notice of Special Interest (NOSI): Long-Term Neurocognitive Consequences of COVID-19 in Individuals Living with HIV and Substance Use Disorders</b>	<a href="#">NOT-DA-21-018</a>	<a href="#">NIDA</a>	Feb 3, 2021	<a href="#">PA-20-184</a> <a href="#">PA-20-183</a> <a href="#">PA-20-200</a> <a href="#">PA-20-195</a> <a href="#">PA-20-194</a> <a href="#">PA-20-196</a> <a href="#">PA-20-146</a>	Sep 8, 2024	R01, R03, R21
<b>Notice of Special Interest (NOSI): Administrative Supplements for the Clinical and Translational Science Award (CTSA) Program to Address COVID-19 Public Health Needs</b>	<a href="#">NOT-TR-21-017</a>	<a href="#">NCATS</a>	Feb 3, 2021	<a href="#">PA-20-272</a>	Aug 17, 2024	333
<b>Notice of Special Interest (NOSI): NIDCR Support for Research on the Physiological Involvement of Oral Cavity in Coronavirus Disease 2019 (COVID-19)</b>	<a href="#">NOT-DE-21-001</a>	<a href="#">NIDCR</a>	Jan 26, 2021	<a href="#">PA-20-185</a> <a href="#">PA-20-195</a>	May 28, 2023	R01, R21
<b>Notice of Special Interest (NOSI): Aging-Relevant Behavioral and Social Research on Coronavirus Disease 2019 (COVID-19)</b>	<a href="#">NOT-AG-21-015</a>	<a href="#">NIA</a>	Jan 26, 2021	<a href="#">PA-20-183</a> <a href="#">PA-20-184</a> <a href="#">PA-20-185</a> <a href="#">PA-20-200</a> <a href="#">PA-20-194</a> <a href="#">PA-20-196</a> <a href="#">PA-20-195</a> <a href="#">PAR-19-374</a> <a href="#">PAR-19-314</a> <a href="#">PAR-19-070</a> <a href="#">PAR-19-071</a> <a href="#">PAR-20-070</a>	May 28, 2023	R01, R03, R21, U19, P01, R21/R33
<b>Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection</b>	<a href="#">NOT-DA-21-011</a>	<a href="#">NIDA</a>	Jan 26, 2021	<a href="#">PA-20-184</a> <a href="#">PA-20-183</a> <a href="#">PA-20-200</a> <a href="#">PA-20-195</a> <a href="#">PA-20-194</a> <a href="#">PA-20-196</a> <a href="#">PA-20-146</a>	Sep 8, 2024	R01, R03, R21
<b>Immune Development in Early Life (IDEaL) (U19 Clinical Trial Not Allowed)</b>	<a href="#">RFA-AI-20-078</a>	<a href="#">NIAID, NIEHS</a>	Jan 12, 2021	<a href="#">RFA-AI-20-078</a>	Jun 5, 2021	U19
<b>Immune Development in Early Life (IDEaL)</b>	<a href="#">RFA-AI-20-077</a>	<a href="#">NIAID, NIEHS</a>	Jan 12, 2021	<a href="#">RFA-AI-20-077</a>	Jun 5, 2021	U01

(U01 Clinical Trial Not Allowed)						
Notice of Special Interest: Promoting Research on COVID-19 and Rheumatic, Musculoskeletal and Skin Diseases	<a href="#">NOT-AR-21-012</a>	<a href="#">NIAMS</a>	Jan 5, 2021	<a href="#">PA-20-185</a> <a href="#">PA-20-195</a> <a href="#">PAR-21-055</a> <a href="#">PAR-21-054</a> <a href="#">PAR-21-053</a>	Nov 19, 2021	R01, R02
Notice of Special Interest: Administrative Supplements for COVID-19 Impacted NIMH Research	<a href="#">NOT-MH-21-120</a>	<a href="#">NIMH</a>	Dec 23, 2020	<a href="#">PA-20-272</a>	Jun 2, 2023	333
Notice of Special Interest (NOSI): Research to Address Vaccine Hesitancy, Uptake, and Implementation among Populations that Experience Health Disparities	<a href="#">NOT-MD-21-008</a>	<a href="#">NIMHD</a> , <a href="#">NIAID</a> , <a href="#">NIAMS</a> , <a href="#">NCI</a> , <a href="#">ORWH</a> , <a href="#">NIMH</a> , <a href="#">NINR</a> , <a href="#">OBSSR</a> , <a href="#">ODP</a> , <a href="#">NHLBI</a> , <a href="#">NIDCR</a> , <a href="#">SGMRO</a>	Dec 17, 2020	<a href="#">PA-20-183</a> <a href="#">PA-20-185</a>	Jan 8, 2022	R01
Notice of Special Interest (NOSI): Availability of Emergency Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs	<a href="#">NOT-TR-21-011</a>	<a href="#">NCATS</a>	Dec 17, 2020	<a href="#">PAR-18-940</a> <a href="#">PAR-18-464</a> <a href="#">PAR-15-304</a> <a href="#">RFA-TR-14-009</a>	Jun 2, 2021	333
Notice of Special Interest: Impact of COVID-19 on Dementia Risk, Progression and Outcomes in ADRD Populations	<a href="#">NOT-NS-21-037</a>	<a href="#">NINDS</a>	Mar 15, 2021	<a href="#">PAR-20-072</a>	May 6, 2021	333
Emergency Awards: Notice of Special Interest (NOSI) on Pan-Coronavirus Vaccine Development Program Projects	<a href="#">NOT-AI-21-002</a>	<a href="#">NIAID</a>	Nov 10, 2020	<a href="#">PAR-20-072</a>	Jun 12, 2021	PO1
Notice of Special Interest (NOSI): Effects of smoking and vaping on the risk and outcome of COVID-19 infection	<a href="#">NOT-DA-20-084</a>	<a href="#">NIDA</a>	Oct 27, 2020	<a href="#">PA-20-183</a> <a href="#">PA-20-200</a> <a href="#">PA-20-195</a>	Sep 8, 2024	R01, R03, R21
Notice of Special Interest (NOSI): Administrative Supplements to SEPA Awards to	<a href="#">NOT-GM-21-032</a>	<a href="#">NIGMS</a>	Mar 10, 2021	<a href="#">PAR-20-072</a>	May 1, 2021	333

Develop Innovative Educational Resources to Address SARS-CoV-2 Vaccine Hesitancy						
Notice of Special Interest (NOSI): The Influence of Host Resilience on Heterogeneity of Acute Respiratory Distress Syndrome/Acute Lung Injury (ARDS/ALI)	<a href="#">NOT- HL-20-814</a>	<a href="#">NHLBI</a>	Sept 15, 2020	<a href="#">PAR-20-183</a> <a href="#">PAR-20-185</a>	July 6, 2024	U01
Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2	<a href="#">NOT- AI-20-065</a>	<a href="#">NIAID</a>	Aug 13, 2020	<a href="#">PAR-18-633</a>	Sep 1, 2021	U01
Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities	<a href="#">NOT- MD-20-025</a>	<a href="#">NIMHD, NCI, NIDA, NLM, ODP, OBSSR, NIMH, NIAMS</a>	Aug 13, 2020	<a href="#">PA-20-185</a>	May 8, 2023	R01
Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed)	<a href="#">PAR-20-256</a>	<a href="#">NIAID</a>	Jul 13, 2020	<a href="#">PAR-20-256</a>	Jul 8, 2021	S10
Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)	<a href="#">NOT- AI-20-059</a>	<a href="#">NIAID</a>	Jul 6, 2020	<a href="#">PA-20-135</a>	Jul 2, 2021	333
Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive	<a href="#">NOT- OD-20-129</a>	<a href="#">NIH, NCI, NHGRI, NCCIH, NINDS, ORIP, NIMHD, NIA, NIDCR, NIAID, NIAMS, NIEHS, NCATS, NIDCD, NICHD, NIDDK, NHLBI</a>	Jun 25, 2020	<a href="#">PA-18-591</a> (Parent Admin Supplement) <a href="#">PA-18-935</a> (Urgent Supplement)	Jul 13, 2021	333

Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome for the INCLUDE Project						
Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders	<a href="#">NOT-DC-20-008</a>	<a href="#">NIDCD</a>	Jun 4, 2020	<a href="#">PA-18-334</a> <a href="#">PA-20-185</a> <a href="#">PA-20-184</a> <a href="#">PA-20-196</a> <a href="#">PA-20-195</a> <a href="#">PA-19-270</a> <a href="#">PA-19-271</a> <a href="#">PA-19-273</a> <a href="#">PA-19-272</a>	Sep 8, 2022	R01, R21, R41/R42, R43/R44
Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)	<a href="#">NOT-ES-20-020</a>	<a href="#">NIEHS</a>	Apr 10, 2020	<a href="#">PA-18-591</a> (Parent Admin Supplement) <a href="#">PA-18-935</a> (Urgent Supplement) <a href="#">RFA-ES-19-011</a>	May 4, 2021	333, R21
Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities	<a href="#">NOT-MD-20-019</a>	<a href="#">NIMHD</a> , <a href="#">NIA</a> , <a href="#">NIAAA</a> , <a href="#">NIMH</a> , <a href="#">ODP</a>	Apr 9, 2020	<a href="#">PA-18-591</a> (Parent Admin Supplement) <a href="#">PA-18-935</a> (Urgent Supplement)	May 1, 2021	333
Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus	<a href="#">NOT-TR-20-017</a>	<a href="#">NCATS</a>	Apr 9, 2020	<a href="#">PA-20-135</a>	Jan 26, 2022	333
Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus	<a href="#">NOT-TR-20-016</a>	<a href="#">NCATS</a>	Apr 9, 2020	<a href="#">PA-18-591</a>	Jan 26, 2022	333



Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19)	<a href="#">NOT-ES-20-015</a>	<a href="#">NIEHS</a>	Apr 8, 2020	<a href="#">RFA-ES-19-011</a>	May 4, 2021	333, R21
Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)	<a href="#">NOT-AG-20-022</a>	<a href="#">NIA, NIMH</a>	Apr 2, 2020	<a href="#">PA-18-591</a> (Parent Admin Supplement) <a href="#">PA-18-935</a> (Urgent Supplement)	May 1, 2021	333
Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need	<a href="#">NOT-TR-20-011</a>	<a href="#">NCATS</a>	Mar 24, 2020	<a href="#">PA-18-591</a> (Parent Admin Supplement) <a href="#">PA-18-935</a> (Urgent Supplement)	Jul 10, 2021	333, U01, R21, U54
Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Trial Optional)	<a href="#">PA-20-135</a>	<a href="#">NIH, NCATS, NCCIH, NCI, NHGRI, NIA, NIAAA, NIAID, NIAMS, NIBIB, NICHD, NIDCD, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINR, NLM, ORWH, OSC</a>	Mar 10, 2020	<a href="#">PA-20-135</a>	Sep 8, 2025	333
The Intersection of Sex and Gender Influences on Health and Disease (R01 Clinical Trial Optional)	<a href="#">RFA-OD-19-029</a>	<a href="#">ORWH, NCCIH, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIDA, NIDCR, NIEHS, NIMH, NINR</a>	Sep 27, 2019	<a href="#">PA-20-272</a>	Nov 27, 2021	R01
Notice of Special Interest (NOSI): Administrative Supplements to FIC Awards for COVID-19-related Research in Low- or Middle-Income Countries	<a href="#">NOT-TW-21-004</a>	<a href="#">FIC</a>	Mar 23, 2021	<a href="#">PA-20-272</a> <a href="#">NOT-TW-21-003</a>	May 15, 2021	333
Notice of Special Interest (NOSI): Administrative Supplements for COVID-19-Impacted FIC Research Training and Education Awards	<a href="#">NOT-TW-21-003</a>	<a href="#">FIC</a>	Mar 23, 2021	<a href="#">PA-20-272</a> <a href="#">NOT-TW-21-004</a>	May 15, 2021	333

Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium Coordinating Center (U24 Clinical Trial Not Allowed)	<a href="#">RFA- AG-21-035</a>	<a href="#">NIA, ORWH, OBSSR</a>	April 8, 2021	<a href="#">PAR-21-213, U01</a> Research Project (Cooperative Agreements)	June 10, 2021	U24
Emergency Award: Social, Behavioral, and Economic Research on COVID-19 Consortium (U01 Clinical Trial Not Allowed)	<a href="#">PAR-21-213</a>	<a href="#">NIA, NIDA, ORWH, NIMH, NIAA, NIMHD, OBSSR, NEI</a>	April 6, 2021	<a href="#">U01</a> Research Project (Cooperative Agreements)	Nov 9, 2021	U01

If you are interested in applying for any of the grants, please email Michelle Parra ([MMParra@salud.unm.edu](mailto:MMParra@salud.unm.edu)).

For a full listing of COVID-19 through NIH, please access the following site: <https://grants.nih.gov/grants/guide/COVID-Related.cfm>.

## Citing the CTSC

When citing the CTSC, please be sure to include our Grant numbers:



*Thank you!*

## HS in the News

For additional Health Sciences news, please visit:  
<http://hscnews.unm.edu/>

### News or corrections?

Please contact [the Newsletter Team](#).

The University Of New Mexico Mailing Address:  
One University of New Mexico  
MSC 08 4635  
Albuquerque, NM 87131